Neil McFarlane
Chief Executive Officer bei ZEVRA THERAPEUTICS, INC.
Vermögen: 380 125 $ am 31.03.2024
Profil
Mr. Neil F.
McFarlane is a President, Chief Executive Officer & Director at Zevra Therapeutics, Inc. and an Independent Director at Collegium Pharmaceutical, Inc. He is on the Board of Directors at Zevra Therapeutics, Inc. and Collegium Pharmaceutical, Inc. Mr. McFarlane was previously employed as a Chief Executive Officer by Adamas Pharmaceuticals LLC, a Chief Operating Officer by Travere Therapeutics, Inc., a Vice President by UCB, Inc., and a Chief Executive Officer & Director by Adamas Pharmaceuticals, Inc. He received his undergraduate degree from the University of Florida and a graduate degree from the University of Florida.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 27.03.2024 | 9 792 ( 0,03% ) | 380 125 $ | 31.03.2024 |
Aktive Positionen von Neil McFarlane
| Unternehmen | Position | Beginn |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Director/Board Member | 06.04.2022 |
| ZEVRA THERAPEUTICS, INC. | Chief Executive Officer | 10.10.2023 |
Ehemalige bekannte Positionen von Neil McFarlane
| Unternehmen | Position | Ende |
|---|---|---|
| Adamas Pharmaceuticals, Inc. | Chief Executive Officer | 01.11.2021 |
| ADAMAS PHARMACEUTICALS, INC. | Chief Executive Officer | 01.01.2021 |
| TRAVERE THERAPEUTICS, INC. | Chief Operating Officer | 31.05.2019 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Neil McFarlane
| University of Florida | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
| Adamas Pharmaceuticals, Inc. |
